P260: Survival in eteplirsen-treated vs Duchenne muscular dystrophy natural history patients: An indirect treatment comparison using real-world data

• Erin O’Rourke,
• Joel Iff,
• Nicolae Done,
• Ed Tuttle,
• Yi Zhong,
• Fangzhou Wei,
• Basil Darras,
• Craig McDonald,
• Eugenio Mercuri,
• Francesco Muntoni

Affiliations

Erin O’Rourke

Sarepta Therapeutics, Inc., Cambridge, MA

Joel Iff

Sarepta Therapeutics, Inc., Cambridge, MA

Nicolae Done

Analysis Group, Inc., Boston, MA

Ed Tuttle

Analysis Group, Inc., Boston, MA

Yi Zhong

Analysis Group, Inc., Boston, MA

Fangzhou Wei

Analysis Group, Inc., Boston, MA

Basil Darras

Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA

Craig McDonald

University of California Davis Health System, Sacramento, CA

Eugenio Mercuri

Paediatric Neurology and Centro Clinico Nemo, Catholic University, Rome, Italy

Francesco Muntoni

Dubowitz Neuromuscular Centre, Great Ormond Street Hospital for Children, London, UK